Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b
Objective: To investigate the effect of Atorvastatin vs. placebo on some inflammatory markers in patients with multiple sclerosis treated by interferone beta-1b.To achieve the aim of this study, a randomized control comparative trial was adopted. Patients and Methods: A total of 100 patients with mu...
Saved in:
Main Authors: | , |
---|---|
Format: | Book |
Published: |
University of Mosul,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_df5f76ce6f5a484a8cace678db6e52e6 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Farah Waleed Mahmood |e author |
700 | 1 | 0 | |a Shamil Hashim Othman |e author |
245 | 0 | 0 | |a Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b |
260 | |b University of Mosul, |c 2019-06-01T00:00:00Z. | ||
500 | |a 1680-2594 | ||
500 | |a 2664-2522 | ||
500 | |a 10.33899/iphr.2019.161191 | ||
520 | |a Objective: To investigate the effect of Atorvastatin vs. placebo on some inflammatory markers in patients with multiple sclerosis treated by interferone beta-1b.To achieve the aim of this study, a randomized control comparative trial was adopted. Patients and Methods: A total of 100 patients with multiple sclerosis were recruited and investigated for some inflammatory markers which included, interleukin-2, tumor necrosis factor-α, C-reactive protein, and erythrocyte sedimentation rate. The patients were divided into 2 groups, namely the atorvastatin group which consisted of 50 patients and the placebo group which consisted of 50 patients. The patient groups were followed- up for 12 weeks during which the above parameters were measured before starting therapies and at the end of the follow-up period using commercially available kits. The patient groups were compared with the control group consisted of 50 apparently healthy subjects. Results: The IL-2,TNF-α,CRP and ESR at baseline in both patient groups were found significantly elevated as compared with the control group ( p< 0.001) . The use of atorvastatinhas resulted in significant decrease on the above parameters with non-significant effects in the placebogroup. Atorvastatinappeared to be superior in compared with the placebo group. Conclusion: The use of atorvastatinfor 12 weeks in patients withmultiple sclerosis treated by interferone-beta has beneficial effect on some inflammatory markers studied in this research( IL-2,TNF-α,CRP and ESR). | ||
546 | |a EN | ||
690 | |a multiple sclerosis | ||
690 | |a atorvastatin | ||
690 | |a interferone-beta-1b | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n المجلة العراقية للصيدلة, Vol 14, Iss 1, Pp 23-31 (2019) | |
787 | 0 | |n https://iphr.mosuljournals.com/article_161191_82c204c1ff72855d6f02f26b448bde0c.pdf | |
787 | 0 | |n https://doaj.org/toc/1680-2594 | |
787 | 0 | |n https://doaj.org/toc/2664-2522 | |
856 | 4 | 1 | |u https://doaj.org/article/df5f76ce6f5a484a8cace678db6e52e6 |z Connect to this object online. |